NeuBase Therapeutics Inc. (NBSE) and Gamida Cell Ltd. (NASDAQ:GMDA) Comparison side by side

This is a contrast between NeuBase Therapeutics Inc. (NASDAQ:NBSE) and Gamida Cell Ltd. (NASDAQ:GMDA) based on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NeuBase Therapeutics Inc. 5 0.00 N/A -3.17 0.00
Gamida Cell Ltd. 7 0.00 N/A -2.47 0.00

In table 1 we can see NeuBase Therapeutics Inc. and Gamida Cell Ltd.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides us the return on equity, net margins and return on assets of both companies.

Net Margins Return on Equity Return on Assets
NeuBase Therapeutics Inc. 0.00% -75.8% -71.5%
Gamida Cell Ltd. 0.00% -662.4% -130.2%

Liquidity

NeuBase Therapeutics Inc. has a Current Ratio of 3.7 and a Quick Ratio of 3.7. Competitively, Gamida Cell Ltd.’s Current Ratio is 6.5 and has 6.5 Quick Ratio. Gamida Cell Ltd.’s better ability to pay short and long-term obligations than NeuBase Therapeutics Inc.

Institutional and Insider Ownership

Roughly 3.1% of NeuBase Therapeutics Inc. shares are held by institutional investors while 13.1% of Gamida Cell Ltd. are owned by institutional investors. Competitively, Gamida Cell Ltd. has 65.61% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
NeuBase Therapeutics Inc. 21.82% 48.97% 109.05% 95.38% 35.83% 195.35%
Gamida Cell Ltd. -5.13% -27.31% -51.06% -74.27% 0% -62.78%

For the past year NeuBase Therapeutics Inc. had bullish trend while Gamida Cell Ltd. had bearish trend.

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases in the United States, the European Union, and internationally. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase 3 clinical trials for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, which is in Phase 1 clinical trials for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.